vs
Pacira BioSciences, Inc.（PCRX）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
LiveRamp Holdings, Inc.的季度营收约是Pacira BioSciences, Inc.的1.2倍（$212.2M vs $177.4M），LiveRamp Holdings, Inc.净利率更高（18.8% vs 1.6%，领先17.1%），LiveRamp Holdings, Inc.同比增速更快（8.6% vs 5.0%），过去两年LiveRamp Holdings, Inc.的营收复合增速更高（11.1% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
PCRX vs RAMP — 直观对比
营收规模更大
RAMP
是对方的1.2倍
$177.4M
营收增速更快
RAMP
高出3.6%
5.0%
净利率更高
RAMP
高出17.1%
1.6%
两年增速更快
RAMP
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $212.2M |
| 净利润 | $2.9M | $39.9M |
| 毛利率 | — | 71.9% |
| 营业利润率 | 3.9% | 18.6% |
| 净利率 | 1.6% | 18.8% |
| 营收同比 | 5.0% | 8.6% |
| 净利润同比 | — | 255.7% |
| 每股收益（稀释后） | $0.07 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRAMP
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $212.2M | ||
| Q3 25 | $179.5M | $199.8M | ||
| Q2 25 | $181.1M | $194.8M | ||
| Q1 25 | $168.9M | $188.7M | ||
| Q4 24 | $187.3M | $195.4M | ||
| Q3 24 | $168.6M | $185.5M | ||
| Q2 24 | $178.0M | $176.0M |
净利润PCRXRAMP
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $39.9M | ||
| Q3 25 | $5.4M | $27.4M | ||
| Q2 25 | $-4.8M | $7.7M | ||
| Q1 25 | $4.8M | $-6.3M | ||
| Q4 24 | — | $11.2M | ||
| Q3 24 | $-143.5M | $1.7M | ||
| Q2 24 | $18.9M | $-7.5M |
毛利率PCRXRAMP
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 71.9% | ||
| Q3 25 | 80.9% | 70.2% | ||
| Q2 25 | 77.4% | 70.1% | ||
| Q1 25 | 79.7% | 69.3% | ||
| Q4 24 | 78.7% | 71.9% | ||
| Q3 24 | 76.9% | 72.4% | ||
| Q2 24 | 75.1% | 70.6% |
营业利润率PCRXRAMP
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 18.6% | ||
| Q3 25 | 3.5% | 10.7% | ||
| Q2 25 | 4.7% | 3.7% | ||
| Q1 25 | 1.2% | -6.1% | ||
| Q4 24 | 13.2% | 7.5% | ||
| Q3 24 | -82.8% | 4.0% | ||
| Q2 24 | 15.9% | -3.0% |
净利率PCRXRAMP
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 18.8% | ||
| Q3 25 | 3.0% | 13.7% | ||
| Q2 25 | -2.7% | 4.0% | ||
| Q1 25 | 2.8% | -3.3% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | -85.1% | 0.9% | ||
| Q2 24 | 10.6% | -4.3% |
每股收益（稀释后）PCRXRAMP
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.62 | ||
| Q3 25 | $0.12 | $0.42 | ||
| Q2 25 | $-0.11 | $0.12 | ||
| Q1 25 | $0.10 | $-0.10 | ||
| Q4 24 | $0.38 | $0.17 | ||
| Q3 24 | $-3.11 | $0.03 | ||
| Q2 24 | $0.39 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $403.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $962.3M |
| 总资产 | $1.2B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXRAMP
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $403.4M | ||
| Q3 25 | $246.3M | $376.9M | ||
| Q2 25 | $445.9M | $371.1M | ||
| Q1 25 | $493.6M | $420.8M | ||
| Q4 24 | $484.6M | $384.3M | ||
| Q3 24 | $453.8M | $348.4M | ||
| Q2 24 | $404.2M | $342.7M |
总债务PCRXRAMP
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXRAMP
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $962.3M | ||
| Q3 25 | $727.2M | $943.8M | ||
| Q2 25 | $757.8M | $947.8M | ||
| Q1 25 | $798.5M | $948.9M | ||
| Q4 24 | $778.3M | $957.7M | ||
| Q3 24 | $749.6M | $932.1M | ||
| Q2 24 | $879.3M | $951.9M |
总资产PCRXRAMP
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.5B | $1.2B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.6B | $1.2B |
负债/权益比PCRXRAMP
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RAMP
暂无分部数据
